Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2020 May 29;28(3):249–271. doi: 10.3727/096504019X15766663541105

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

Copyright © 2020 Cognizant, LLC.

This article is licensed under a Creative Commons Attribution-NonCommercial NoDerivatives 4.0 International License.

PMC Copyright notice

Treatment response of drug-eluting beads transarterial chemoembolization (DEB-TACE) treatment. (A) The complete response (CR), partial response (PR), objective response rate (ORR), stable disease (SD), and progressive disease (PD) within 1–3 months after treatments were 19.9%, 59.7%, 79.6%, 14.4%, and 6.0% in 367 patients. (B) In 219 patients with PR, 35.2%, 48.4%, and 16.4% patients had necrosis rates of ≥80%, 50%–80%, and <50%. (C) In terms of the treated nodules, 28.6%, 49.5%, 78.1%, 15.4%, and 6.4% nodules were CR, PR, ORR, SD, and PD, respectively. (D) In nodules achieving PR, 43.9%, 40.3%, and 15.8% had necrosis rates of ≥80%, 50%–80% and <50%.